Side-by-side comparison of AI visibility scores, market position, and capabilities
Non-hallucinogenic psychedelic drug developer using AI to design therapeutics without dissociation; $25.5M raised backed by OpenAI/Neuralink founders with FDA Phase I approval for MSD-001 in 2024.
Mindstate Design Labs is a Los Angeles-based clinical-stage biotech developing non-hallucinogenic psychedelic therapeutics — using computational neuroscience and machine learning to engineer psychedelic-inspired molecules that activate the neural mechanisms associated with therapeutic benefit (neuroplasticity, serotonin receptor modulation) while minimizing or eliminating the dissociative hallucinogenic effects that limit psychedelic therapy to clinical settings. A Y Combinator W21 graduate, Mindstate raised $25.5 million total, achieved $1.3 million in revenue in 2024 with a 19-person team, and received FDA and EMA approval for Phase I human trials of lead program MSD-001 in 2024, backed by founders of OpenAI, Neuralink, Coinbase, and Initialized Capital.
Veterinary diagnostics leader with $3.81B FY2024 revenue; 130,000+ analyzer installed base; AI-powered inVue Dx digital cytology; VetConnect data platform; pet humanization tailwind.
IDEXX Laboratories is the global leader in veterinary diagnostics and information technology for companion animal healthcare, founded in 1983 by David Shaw in Westbrook, Maine, where it remains headquartered. The company trades on Nasdaq (IDXX) and reported $3.81 billion in revenues for FY2024, maintaining its dominant position in point-of-care veterinary diagnostics through an installed base of over 130,000 Catalyst chemistry analyzers, ProCyte hematology systems, and SNAP rapid assay devices deployed in veterinary clinics worldwide. CEO Jay Mazelsky has continued IDEXX's expansion into AI-powered diagnostics and digital pathology, building on over four decades of veterinary-specific product development.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.